Physostigmine
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Physostigmine Salicylate
CONTRAINDICATIONS
Physostigmine Salicylate (physostigmine salicylate (injection)) Injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine).
For post-anesthesia, the concomitant use of atropine with physostigmine salicylate (physostigmine salicylate (injection)) is not recommended, since the atropine antagonizes the action of physostigmine.
Last reviewed on RxList: 11/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Physostigmine Salicylate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
